MET in gastric cancer with liver metastasis: The relationship betweenMETamplification and Met overexpression in primary stomach tumors and liver metastasis-Reference-Cited by-同舟云学术

MET in gastric cancer with liver metastasis: The relationship betweenMETamplification and Met overexpression in primary stomach tumors and liver metastasis

Published:2018-05-22 Issue:8 Volume:117 Page:1679-1686
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Kim Han S.¹²^ORCID,Chon Hong J.³,Kim Hyunki⁴,Shin Su-Jin⁵,Wacheck Volker⁶,Gruver Aaron M.⁷,Kim Jong S.⁸,Rha Sun Y.¹²,Chung Hyun C.¹²

Affiliation:

1. Division of Medical Oncology; Department of Internal Medicine; Yonsei Cancer Center; Yonsei University College of Medicine; Seoul South Korea

2. Song-Dang Institute for Cancer Research; Yonsei University College of Medicine; Seoul South Korea

3. Division of Medical Oncology; Department of Internal Medicine; CHA University Bundang Medical Center; Seongnam South Korea

4. Department of Pathology; Yonsei University College of Medicine; Seoul South Korea

5. Department of Pathology; Hanyang University College of Medicine; Seoul South Korea

6. Oncology Medical; Lilly Research Laboratories; A Division of Eli Lilly and Company; Lilly Corporate Center; Indianapolis Indiana

7. Diagnostic and Experimental Pathology; Eli Lilly and Company; Indianapolis Indiana

8. Eli Lilly and Company; Seoul South Korea

Funder

Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea

Eli Lilly and Company

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jso.25097/fullpdf

Reference30 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target;Gravalos;Ann Oncol,2008

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

4. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014

5. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial;Wilke;Lancet Oncol,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic biology and therapeutic strategies of liver metastasis from gastric cancer;Critical Reviews in Oncology/Hematology;2024-10

2. Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review;World Journal of Gastrointestinal Oncology;2024-08-15

3. Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer;World Journal of Gastrointestinal Oncology;2024-06-15

4. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer;Frontiers in Oncology;2024-06-14

5. The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy;Pharmaceuticals;2024-03-30